Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group

Kristin R. Knight, Lu Chen, David Freyer, Richard Aplenc, Mary Bancroft, Bonnie Bliss, Ha Dang, Biljana Gillmeister, Eleanor Hendershot, Dale F. Kraemer, Lanie Lindenfeld, Jane Meza, Edward A. Neuwelt, Bradley H Pollock, Lillian Sung

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. Patients and Methods Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment. Hearing evaluations were conducted at baseline, before each cisplatin cycle, and at the end of therapy. Audiologic results were assessed and graded by the testing audiologist and by two central review audiologists using the American Speech-Language-Hearing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), and Brock Ototoxicity Grades (Brock). One central reviewer also used the Society for Industrial and Organizational Psychology Ototoxicity Scale (SIOP). Results At the end of treatment, the prevalence of any degree of ototoxicity ranged from 40% to 56%, and severe ototoxicity ranged from 7% to 22%. Compared with CTCAE, SIOP detected significantly more ototoxicity ( P = .004), whereas Brock criteria detected significantly fewer patients with any or severe ototoxicity ( P < .001 for both). SIOP detected ototoxicity earlier than did the other scales. Agreement between the central reviewers and the institutional audiologist was almost perfect for ASHA and Brock, whereas the poorest agreement occurred with CTCAE. Conclusion The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin. Future studies should evaluate inter-rater reliability of the SIOP scale.

Original languageEnglish (US)
Pages (from-to)440-445
Number of pages6
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume35
Issue number4
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

American Speech-Language-Hearing Association
Cisplatin
Terminology
Prospective Studies
Drug Therapy
Hearing
Industrial Psychology
Audiometry
Therapeutics
Pediatrics
Audiologists

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1) : A Report From the Children's Oncology Group. / Knight, Kristin R.; Chen, Lu; Freyer, David; Aplenc, Richard; Bancroft, Mary; Bliss, Bonnie; Dang, Ha; Gillmeister, Biljana; Hendershot, Eleanor; Kraemer, Dale F.; Lindenfeld, Lanie; Meza, Jane; Neuwelt, Edward A.; Pollock, Bradley H; Sung, Lillian.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 35, No. 4, 01.02.2017, p. 440-445.

Research output: Contribution to journalArticle

Knight, KR, Chen, L, Freyer, D, Aplenc, R, Bancroft, M, Bliss, B, Dang, H, Gillmeister, B, Hendershot, E, Kraemer, DF, Lindenfeld, L, Meza, J, Neuwelt, EA, Pollock, BH & Sung, L 2017, 'Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 35, no. 4, pp. 440-445. https://doi.org/10.1200/JCO.2016.69.2319
Knight, Kristin R. ; Chen, Lu ; Freyer, David ; Aplenc, Richard ; Bancroft, Mary ; Bliss, Bonnie ; Dang, Ha ; Gillmeister, Biljana ; Hendershot, Eleanor ; Kraemer, Dale F. ; Lindenfeld, Lanie ; Meza, Jane ; Neuwelt, Edward A. ; Pollock, Bradley H ; Sung, Lillian. / Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1) : A Report From the Children's Oncology Group. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 ; Vol. 35, No. 4. pp. 440-445.
@article{177417342b864feb8223da9b36c567ee,
title = "Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group",
abstract = "Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. Patients and Methods Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment. Hearing evaluations were conducted at baseline, before each cisplatin cycle, and at the end of therapy. Audiologic results were assessed and graded by the testing audiologist and by two central review audiologists using the American Speech-Language-Hearing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), and Brock Ototoxicity Grades (Brock). One central reviewer also used the Society for Industrial and Organizational Psychology Ototoxicity Scale (SIOP). Results At the end of treatment, the prevalence of any degree of ototoxicity ranged from 40{\%} to 56{\%}, and severe ototoxicity ranged from 7{\%} to 22{\%}. Compared with CTCAE, SIOP detected significantly more ototoxicity ( P = .004), whereas Brock criteria detected significantly fewer patients with any or severe ototoxicity ( P < .001 for both). SIOP detected ototoxicity earlier than did the other scales. Agreement between the central reviewers and the institutional audiologist was almost perfect for ASHA and Brock, whereas the poorest agreement occurred with CTCAE. Conclusion The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin. Future studies should evaluate inter-rater reliability of the SIOP scale.",
author = "Knight, {Kristin R.} and Lu Chen and David Freyer and Richard Aplenc and Mary Bancroft and Bonnie Bliss and Ha Dang and Biljana Gillmeister and Eleanor Hendershot and Kraemer, {Dale F.} and Lanie Lindenfeld and Jane Meza and Neuwelt, {Edward A.} and Pollock, {Bradley H} and Lillian Sung",
year = "2017",
month = "2",
day = "1",
doi = "10.1200/JCO.2016.69.2319",
language = "English (US)",
volume = "35",
pages = "440--445",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1)

T2 - A Report From the Children's Oncology Group

AU - Knight, Kristin R.

AU - Chen, Lu

AU - Freyer, David

AU - Aplenc, Richard

AU - Bancroft, Mary

AU - Bliss, Bonnie

AU - Dang, Ha

AU - Gillmeister, Biljana

AU - Hendershot, Eleanor

AU - Kraemer, Dale F.

AU - Lindenfeld, Lanie

AU - Meza, Jane

AU - Neuwelt, Edward A.

AU - Pollock, Bradley H

AU - Sung, Lillian

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. Patients and Methods Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment. Hearing evaluations were conducted at baseline, before each cisplatin cycle, and at the end of therapy. Audiologic results were assessed and graded by the testing audiologist and by two central review audiologists using the American Speech-Language-Hearing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), and Brock Ototoxicity Grades (Brock). One central reviewer also used the Society for Industrial and Organizational Psychology Ototoxicity Scale (SIOP). Results At the end of treatment, the prevalence of any degree of ototoxicity ranged from 40% to 56%, and severe ototoxicity ranged from 7% to 22%. Compared with CTCAE, SIOP detected significantly more ototoxicity ( P = .004), whereas Brock criteria detected significantly fewer patients with any or severe ototoxicity ( P < .001 for both). SIOP detected ototoxicity earlier than did the other scales. Agreement between the central reviewers and the institutional audiologist was almost perfect for ASHA and Brock, whereas the poorest agreement occurred with CTCAE. Conclusion The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin. Future studies should evaluate inter-rater reliability of the SIOP scale.

AB - Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. Patients and Methods Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment. Hearing evaluations were conducted at baseline, before each cisplatin cycle, and at the end of therapy. Audiologic results were assessed and graded by the testing audiologist and by two central review audiologists using the American Speech-Language-Hearing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), and Brock Ototoxicity Grades (Brock). One central reviewer also used the Society for Industrial and Organizational Psychology Ototoxicity Scale (SIOP). Results At the end of treatment, the prevalence of any degree of ototoxicity ranged from 40% to 56%, and severe ototoxicity ranged from 7% to 22%. Compared with CTCAE, SIOP detected significantly more ototoxicity ( P = .004), whereas Brock criteria detected significantly fewer patients with any or severe ototoxicity ( P < .001 for both). SIOP detected ototoxicity earlier than did the other scales. Agreement between the central reviewers and the institutional audiologist was almost perfect for ASHA and Brock, whereas the poorest agreement occurred with CTCAE. Conclusion The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin. Future studies should evaluate inter-rater reliability of the SIOP scale.

UR - http://www.scopus.com/inward/record.url?scp=85027247677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027247677&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.69.2319

DO - 10.1200/JCO.2016.69.2319

M3 - Article

C2 - 27937095

AN - SCOPUS:85027247677

VL - 35

SP - 440

EP - 445

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -